MedTrace Logo

Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

NCT00623701 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2013-11-08

No results posted yet for this study

Summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Conditions

Interventions

BIOLOGICAL

Allerslit forte

sublingual placebo preparation, daily

BIOLOGICAL

Allerslit forte

Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily

Sponsors & Collaborators

  • Allergopharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Kristian Reich, Professor · not affiliated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-10-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623701 on ClinicalTrials.gov